
ASMB
Assembly Biosciences Inc.
$24.70
-$0.80(-3.14%)
--
Overall
--
Value
--
Tech
--
Quality
Market Cap
$196.56M
Volume
122.38K
52W Range
$7.75 - $27.17
Target Price
$31.67
Order:
Income Statement
Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||
Total Revenue | -- | -- | $9.0M | $14.8M | $16.0M | $79.1M | $6.3M | $153.0K | $7.2M | $28.5M | ||
Total Revenue | -- | -- | $9.0M | $14.8M | $16.0M | $79.1M | $6.3M | $153.0K | $7.2M | $28.5M | ||
COST OF GOODS SOLD | ||||||||||||
Cost of Revenue | -- | -- | $-4.6M | -- | -- | -- | -- | -- | -- | -- | ||
GROSS PROFIT | ||||||||||||
Gross Profit | -- | -- | $9.0M | -- | -- | $79.1M | $6.3M | $153.0K | $7.2M | $28.5M | ||
OPERATING EXPENSES | ||||||||||||
Operating Expenses | $-29.7M | $-45.3M | $-61.2M | $-107.5M | $-118.7M | $143.9M | $138.9M | $94.1M | $71.8M | $73.9M | ||
Research & Development | $18.4M | $33.1M | $44.2M | $72.7M | $85.8M | $106.8M | $68.5M | $70.0M | $48.9M | $55.9M | ||
Research Expense | $18.4M | $33.1M | $44.2M | $72.7M | $85.8M | $106.8M | $68.5M | $70.0M | $48.9M | $55.9M | ||
Selling, General & Administrative | $11.3M | $12.2M | $17.0M | $34.8M | $32.9M | $37.1M | $28.8M | $24.1M | $22.9M | $18.0M | ||
General & Administrative Expenses | $11.3M | $12.2M | $17.0M | $34.8M | $32.9M | $37.1M | $28.8M | $24.1M | $22.9M | $18.0M | ||
Salaries & Wages | $-7.9M | $-5.0M | $-8.6M | $-28.5M | $-20.6M | -- | -- | -- | $5.1M | $3.1M | ||
Depreciation & Amortization | $-65.0K | $-80.3K | $-219.0K | $-600.0K | $-500.0K | $700.0K | $500.0K | $500.0K | $500.0K | -- | ||
Depreciation & Amortization | $-65.0K | $-80.3K | $-219.0K | $-600.0K | $-500.0K | $700.0K | $500.0K | $500.0K | $500.0K | -- | ||
Other Operating Expenses | -- | -- | -- | $-107.5M | $-118.7M | $-747.0K | $-663.0K | $-672.0K | $-575.0K | $-711.0K | ||
OPERATING INCOME | ||||||||||||
Operating income | $-29.7M | $-45.3M | $-61.2M | $-107.5M | $-118.7M | $-64.8M | $-132.7M | $-94.1M | $-64.6M | $-45.4M | ||
EBITDA | $-28.4M | $-44.8M | $-51.6M | $-89.2M | $-99.6M | $-64.1M | $-90.6M | $-92.4M | $-64.2M | $-43.4M | ||
NON-OPERATING ITEMS | ||||||||||||
Intinc | $1.2M | $1.5M | $983.0K | $3.1M | $4.3M | $2.6M | $302.0K | $1.0M | $3.5M | $5.6M | ||
Net Non-Operating Interest Income/Expense | $1.2M | $1.5M | $983.0K | $3.1M | $4.3M | $2.6M | $302.0K | $1.0M | $3.5M | $5.6M | ||
Gain on Sale of Securities | $-27.0K | $-1.1M | $-615.0K | $231.0K | $4.0K | -- | -- | -- | -- | -- | ||
Other Income/Expense | $27.0K | $1.1M | $-8.4M | $-14.8M | $-16.0M | $-37.0M | $22.7M | -- | $-2.7M | $-28.3M | ||
Other Special Charges | -- | -- | $9.0M | $14.8M | $16.0M | $37.0M | $6.3M | -- | $2.7M | $28.3M | ||
SPECIAL ITEMS | ||||||||||||
Restructring And Mn A Income | -- | -- | -- | -- | $-2.1M | $3.8M | $1.6M | $1.1M | -- | -- | ||
Special Income Charges | -- | -- | -- | -- | $2.1M | $-3.8M | $-41.6M | $-1.1M | -- | -- | ||
Impairment of Capital Assets | -- | -- | -- | -- | -- | -- | $41.6M | -- | -- | -- | ||
PRE-TAX INCOME | ||||||||||||
EBIT | $-28.5M | $-44.9M | $-51.9M | $-89.7M | $-98.4M | $-64.8M | $-91.0M | $-93.1M | $-64.6M | $-39.8M | ||
Pre-Tax Income | $-28.5M | $-44.9M | $-51.9M | $-89.7M | $-98.4M | $-62.2M | $-132.4M | $-93.1M | $-61.2M | $-39.8M | ||
INCOME TAX | ||||||||||||
Tax Provision | -- | $-617.7K | $-9.1M | $1.1M | $-774.0K | -- | $-2.5M | -- | $33.0K | $330.0K | ||
NET INCOME | ||||||||||||
Net Income | $-28.5M | $-44.3M | $-42.8M | $-90.8M | $-97.6M | $-62.2M | $-129.9M | $-93.1M | $-61.2M | $-40.2M | ||
Net Income (Continuing Operations) | $-28.5M | $-44.3M | $-42.8M | $-90.8M | $-97.6M | $-62.2M | $-129.9M | $-93.1M | $-61.2M | $-40.2M | ||
Net Income (Discontinued Operations) | $-28.5M | $-44.3M | $-42.8M | $-90.8M | $-97.6M | $-62.2M | $-129.9M | $-93.1M | $-61.2M | $-40.2M | ||
Net Income (Common Stockholders) | $-28.5M | $-44.3M | $-42.8M | $-90.8M | $-97.6M | $-62.2M | $-129.9M | $-93.1M | $-61.2M | $-40.2M | ||
Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-39.4M | ||
TOTALS | ||||||||||||
Total Expenses | $-29.7M | $-45.3M | $61.2M | $-107.5M | $-118.7M | $143.9M | $138.9M | $94.1M | $71.8M | $73.9M | ||
SHARE & EPS DATA | ||||||||||||
Average Shares Outstanding | $15.7M | $17.2M | $17.8M | $22.8M | $26.3M | $3.0M | $3.6M | $4.0M | $4.6M | $6.0M | ||
Average Shares Outstanding (Diluted) | $15.7M | $17.2M | $17.8M | $22.8M | $26.2M | $3.0M | -- | $4.0M | $4.6M | $6.0M | ||
Shares Outstanding | $17.2M | $17.3M | $20.3M | $25.5M | $32.6M | $3.2M | $4.0M | $4.3M | $5.5M | $7.5M | ||
Basic EPS | -- | -- | -- | -- | -- | $-21 | $-36 | $-23.04 | $-13.38 | $-6.69 | ||
Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | $-21 | $-36 | $-23.04 | $-13.38 | $-6.69 | ||
Diluted EPS | $-1.81 | $-2.57 | $-2.41 | $-3.98 | $-3.72 | $-21 | $-36 | $-23.04 | $-13.38 | $-6.69 | ||
Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $-23.04 | $-13.38 | $-6.69 | ||
OTHER METRICS | ||||||||||||
Other Gand A | $11.3M | $12.2M | $17.0M | $34.8M | $32.9M | $37.1M | $28.8M | $24.1M | $22.9M | $18.0M | ||
Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | $700.0K | $29.0M | -- | -- | -- | ||
Rent And Landing Fees | $11.3M | $12.2M | $17.0M | $34.8M | $32.9M | -- | -- | -- | -- | -- | ||
Restruct | -- | -- | -- | -- | $-2.1M | $3.8M | $1.6M | $1.1M | -- | -- |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | ASMB | $24.70 | -3.1% | 122.38K |
3 | ||||
4 | ||||
5 | ||||
6 |
Get Assembly Biosciences Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW